Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

Abstract

Purpose: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with platinum-refractory ovarian cancer. Patients and Methods: Twenty-five patients with platinum- refractory advanced ovarian cancer were treated. Twenty of the patients had failed to respond to platinum-based front-line chemotherapy and five had failed to respond to platinum-based therapy repeated at relapse. One patient had received prior pelvic radiation therapy. Patients were required to have bidimensionally measurable disease. Docetaxel was administered at a dose of 100 mg/m2 intravenously (IV) over 1 hour every 21 days. Twenty patients received no corticosteroid p..